Advanced pancreatic adenocarcinoma: A review of current treatment strategies and developing therapies

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 2, 2015, Pages 68-84

  Teague, Andrea ^a   Lim, Kian Huat ^a   Wang Gillam, Andrea ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemotherapy; immune therapy; metastatic pancreatic cancer; stroma; targeted agents

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BINIMETINIB; CAPECITABINE; CETUXIMAB; CISPLATIN; DALOTUZUMAB; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GANITUMAB; GEMCITABINE; IPILIMUMAB; IRINOTECAN; IRINOTECAN SUCROSOFATE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NECUPARANIB; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PEMETREXED; SELUMETINIB; TIPIFARNIB; TRASTUZUMAB; TUMOR VACCINE; UNINDEXED DRUG; VISMODEGIB;

ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXTRACELLULAR MATRIX; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VOMITING;

EID: 84924787753     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014564775     Document Type: Review

References (89)

1. Almoguera C. Shibata D. Forrester K. Martin J. Arnheim N. Perucho M. (1998) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
2. Androulakis N. Syrigos K. Polyzos A. Aravantinos G. Stathopoulos GP. Ziras N. et al. (2005) Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest 23: 9-12.
3. Ardito C. Grüner B. Takeuchi K. Lubeseder-Martellato C. Teichmann N. Mazur PK. et al. (2012) EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22: 304-317.
4. Bailey JM. Swanson B. Hamada T. Eggers JP. Singh PK. Caffery T. et al. (2008) Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 14: 5995-6004.
5. Berlin J. Catalano P. Thomas J. Kugler JW. Haller DG. Benson A.B. 3rd. (2002) A phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275.
6. Berndt N. Hamilton A. Sebti S. (2011) Targeting protein prenylation for cancer therapy. Nature Rev Cancer 11: 775-791.
7. Bernhard J. Dietrich D. Scheithauer W. Gerber D. Bodoky G. Ruhstaller T. et al. (2008) Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial- SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 26: 3695-3701.
8. Biankin A. Waddell N. Kassahn K. Gingras MC. Muthuswamy LB. Johns AL. et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 339-405.
9. Bodoky G. Timcheva C. Spigel DR. La Stella PJ. Ciuleanu TE. Pover G. et al. (2012) A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 30: 1216-1223.
10. Boeck S. Weigang-Köhler K. Fuchs M. Kettner E. Quietzsch D. Trojan J. et al. (2007) Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 18: 745-751.
11. Boeck S. Wilkowski R. Bruns CJ. Issels RD. Schulz C. Moosmann N. et al. (2007) Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 73: 221-227.
12. Boger PC. Shutt JD. Neale JR. Wilson SJ. Bateman AC. Holloway JW. et al. (2012) Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma. Histopathology 61: 509-517.
13. Burris H. 3rd Moore M. Andersen J. Green MR. Rothenberg ML. Modiano MR. et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-Line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
14. Chen J. Taipale J. Young KE. Maiti T. Beachy P.A. (2002) Small molecule modulation of smoothened activity. Proc Natl Acad Sci U S A 99: 14071-14076.
15. Collins M. Pasca di Magliano M. (2014) Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol 4: 407.
16. Colucci G. Giuliani F. Gebbia V. Biglietto M. Rabitti P. Uomo G. et al. (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and / or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologico dell‘Italia Meridionale. Cancer 94: 902-910.
17. Colucci G. Labianca R. Di Costanzo F. Gebbia V. Carteni G. Massidda B. et al. (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28: 1645-1651.
18. Conroy T. Desseigne F. Ychou M. Bouché O. Guimbaud R. Bécouarn Y. et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
19. Cullinan SA. Moertel CG. Fleming TR. Rubin JR. Krook JE. Everson LK. et al. (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin. JAMA 253: 2061-2067.
20. Cullinan S. Moertel CG. Wieand HS. Schutt AJ. Krook JE. Foley JF. et al. (1990) A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65: 2207-2212.
21. Cunningham D. Chau I. Stocken DD. Valle JW. Smith D. Steward W. et al. (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518.
22. Da Cunha Santos G. Dhani N. Tu D. Chin K. Ludkovski O. Kamel-Reid S. et al. (2010) Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 116: 5599-5607.
23. de Jesus-Acosta A. O'Dwyer P. Ramanathan R. von Hoff D. Maitra A. Rasheed Z. et al. (2014) A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (Pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA). 2014 ASCO Gastrointestinal Cancer Symposium. Abstract No. 257.
24. Ding XZ. Iversen P. Cluck MW. Knezetic JA. Adrian TE. (1999) Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 261: 218-223.
25. Drummond DC. Noble CO. Guo Z. Hong K. Park JW. Kirpotin DB. (2006) Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 66: 3271-3277.
26. Eser S. Schnieke A. Schneider. G. Saur D. (2014) Oncogenic KRAS signaling in pancreatic cancer. Br J Cancer 111: 817-822.
27. Faronato M. Muzzonigro G. Milanese G. Menna C. Bonfigli AR. et al. (2007) Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histol and Histopathol 22: 1109-1118.
28. Fjällskog ML. Lejonklou MH. Oberg KE. Eriksson BK. Janson ET. (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9: 1469-1473.
29. Gourgou-Bourgade S. Bascoul-Mollevi C. Desseigne F. Ychou M. Bouché O. Guimbaud R. et al. (2013) Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE4/ACCORD 11 randomized trial. J Clin Oncol 31: 23-29.
30. Heinemann V. Quietzsch D. Gieseler F. Gonnermann M. Schönekäs H. Rost A. et al. (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952.
31. Herrmann R. Bodoky G. Ruhstaller T. Glimelius B. Bajetta E. Schüller J. et al. (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25: 2212-2217.
32. Hingorani S. Harris W. Beck J. Berdov BA. Wagner SA. Pshevlotsky EM. (2013) A phase Ib study of gemcitabine plus PEGPH 20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. 2013 ASCO Annual Meeting. Abstract No. 4010.
33. Hodi FS. O'Day SJ. McDermott DF. Weber RW. Sosman JA. Haanen JB. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363: 711-723.
34. Hosein PJ. de Lima Lopes G. Pasotrini V.H. Gomez C. Macintyre J. Zayas G. et al. (2013) A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 36: 151-156.
35. Infante JR. Papadopoulos KP. Bendell JC. Patnaik A. Burris H.A. 3rd Rasco D. et al. (2013) A phase Ib study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumors. Eur J Cancer 49: 2077-2085.
36. Infante JR. Matsubayashi H. Sato N. Tonascia J. Klein AP. Riall TA. et al. (2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25: 319-325.
37. Kantoff PW. Higano CS. Shore ND. Berger ER. Small EJ. Penson DF. et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
38. Kennedy RD. Quinn JE. Mullan PB. Johnston PG. Harkin DP. (2004) The role of BRCA 1 in the cellular response to chemotherapy. J Natl Cancer Inst 96: 1659-1668.
39. Kindler HL. Ioka T. Richel DJ. Bennouna J. Létourneau R. Okusaka T. et al. (2011) Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12: 256-262.
40. Kindler HL. Niedzwiecki D. Hollis D. Sutherland S. Schrag D. Hurwitz H. et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622.
41. Ko AH. Tempero MA. Shan YS. Su WC. Lin YL. Dito E. et al. (2013) A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 109: 920-925.
42. Kummer NT. Nowicki TS. Azzi JP. Reyes I. Iacob C. Xie S. et al. (2012) Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction. J Cell Biochem 113: 1998-2008.
43. Le D. Wang-Gillam A. Picozzi V. Greten TF. Crocenzi TS. Springett G.M. et al. (2014) A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: updated results. 2014 Gastrointestinal Cancer Symposium. Abstract No. 177.
44. Leach SD. (2005) Epithelial differentiation in pancreatic development and neoplasia: new niches for nestin and notch. J Clin Gastroenterol 39: S78-S82
45. Li X. Ma Q. Xu Q. Duan W. Lei J. Wu E. (2012) Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Curr Pharm Des 18: 2404-2415.
46. LoRusso PM. Rudin CM. Reddy JC. Tibes R. Weiss GJ. Borad MJ. et al. (2011) Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17: 2502-2511.
47. Louvet C. Labianca R. Hammel P. Lledo G. Zampino MG. André T. et al. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516.
48. Lowery MA. Kelsen DP. Stadler ZK. Yu KH. Janjiqian YY. Ludwig E. et al. (2012) An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 16: 1397-1402.
49. Macdonald JS. McCoy S. Whitehead RP. Igbal S. Wade J.L. 3rd. Giquere JK. et al. (2005) A phase II study of farnesyl transferase inhibitor R 11577 in pancreatic cancer: a Southwest Oncology Group (SWOG 9924) study. Invest New Drugs 23: 485-487.
50. Mahshid Y. Lisy MR. Wang X. Spanbroek R. Flygare J. Christensson B. et al. (2009) High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes. BMC Immunol 10; 2.
51. Moertel C. (1978) Chemotherapy of gastrointestinal cancer. N Engl J Med 299: 1049-1052.
52. Moore MJ. Goldstein D. Hamm J. Figer A. Hecht JR. Gallinger S. et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
53. Moynahan ME. Chiu JW. Koller BH. Jasin M. (1999) Brca 1 controls homology-directed DNA repair. Mol Cell 4: 511-518.
54. Murai J. Huang SY. Das BB. Renaud A. Zhang Y. Doroshow JH. et al. (2012) Trapping of PARP 1 and PARP 2 by clinical PARP inhibitors. Cancer Res 72: 5588-5599.
55. National Cancer Institute NCI Drug Dictionary. Available at: http://www.cancer.gov/drugdictionary?CdrID=533294 (accessed February 1, 2014).
56. National Cancer Institute NCI Drug Directory. Available at: http://www.cancer.gov/drugdictionary?CdrID=425350 (accessed December 22, 2013).
57. National Cancer Institute NCI Drug Directory. Available at: http://www.cancer.gov/drugdictionary?CdrID=586104 (accessed December 22, 2013).
58. National Cancer Institute NCI Drug Directory. Available at: http://www.cancer.gov/drugdictionary?CdrID=723650 (accessed December 22, 2013).
59. National Cancer Institute NCI Drug Dictionary. Available at: http://www.cancer.gov/drugdictionary?CdrID=636196 (accessed December 22, 2013).
60. Navas C. Hernández-Porras I. Schuhmacher AJ. Sibilia M. Guerra C. Barbacid M. (2012) EGF receptor signaling is essential for K-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22: 318-330.
61. Ocean AJ. Pennington KL. Guarino MJ. Sheikh A. Bekaii-Saab T. Serafini AN. et al. (2012) Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase I trial. Cancer 118: 5497-5506.
62. Oettle H. Arnold D. Esser M. Huhn D. Riess H. (2000) Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11: 635-638.
63. Oettle H. Richards D. Ramanathan RK. van Laethem JL. Peeters M. Fuchs M. et al. (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16: 1639-1645.
64. Oettle H. Riess H. Stieler JM. Heil G. Schwaner I. Seraphin J. et al. (2014) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 32: 2423-2429.
65. Olive KP. Jacobetz MA. Davidson CJ. Gopinathan A. McIntyre D. Honess D. et al. (2009) Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
66. Oliver GR. Sugar E. Laheru D. Diaz LA. (2010) Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma. 2010 Gastrointestinal Cancers Symposium. Abstract No. 151.
67. Pelzer U. Schwaner I. Stieler J. Adler M. Seraphin J. Dörken B. et al. (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study Group. Eu J Cancer 47: 1676-1681.
68. Philip PA. Benedetti J. Corless CL. Wong R. O'Reilly EM. Flynn PJ. et al. (2010) Phase III study comparing gemcitabine plus cetuximab in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610.
69. Poplin E. Feng Y. Berlin J. Rothenberg ML. Hochster H. Mitchell E. et al. (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minue infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27: 3778-3785.
70. Rocha Lima CM. Green MR. Rotche R. Miller W.H. Jr. Jeffrey GM. Cisar LA. et al. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776-3783.
71. Rougier P. Riess H. Manges R. Karasek P. Humblet Y. Barone C. et al. (2013) Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eu J Cancer 49: 2633-2642.
72. Sachdev D. Yee D. (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6: 1-12.
73. Saif MW. Oettle H. Vervenne WL. Thomas JP. Spitzer G. Visseren-Grul C. et al. (2009) Randomized double-blind phase II trial comparing gemcitabine plus LY 293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J 15: 339-343.
74. Sideras K. Braat H. Kwekkeboom J. van Eijck CH. Peppelenbosch MP. Sleijfer S. et al. (2014) Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 40: 513-522.
75. Siegel R. Naishadham D. Jemal A. (2013) Cancer statistics. CA Cancer J Clin 63: 11-30.
76. Stathopoulos GP. Syrigos K. Aravantinos G. Polyzos A. Papakotoulas P. Fountzilas G. et al. (2006) A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95: 587-592.
77. Takashima A. Faller DV. (2013) Targeting the RAS oncogene. Expert Opin Ther Targets 17: 507-531.
78. Tobita K. Kijima H. Dowaki S. Kashiwagi H. Ohtani Y. Oida Y. et al. (2003) Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 11: 305-309.
79. Tong WG. Ding XZ. Witt RC. Adrian TE. (2002) Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 1: 929-935.
80. US National Institute of Health Clinical Trials Registry. Available at: http://clinicaltrials.gov (accessed December 22, 2013).
81. van Cutsem E. van de Velde H. Karasek P. Oettle H. Vervenne WL. Szawlowski A. et al. (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22: 1430-1438.
82. von Hoff DD. Ervin T. Arena FP. Chiorean EG. Infante J. Moore M. et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703
83. von Hoff D. Li CP. Wang-Gillam A. Bodoky G. Dean A. Jameson G. (2014) NAPOLI-1: randomized phase 3 study of MM-398 (NAL-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy. ESMO 16th World Congress on Gastrointestinal Cancer. Abstract No.O-0003.
84. von Hoff DD. Penny R. Shack S. Campbell E. Taverna D. Borad M. et al. (2006) Frequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents. J Clin Oncol (Meeting Abstracts) 24: 3071.
85. von Hoff DD. Ramanathan RK. Borad MJ. Laheru DA. Smith LS. Wood TE. et al. (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I / II trial. J Clin Oncol 29: 4548-4554.
86. Wasilewicz MP. Kolodziej B. Bojulko T. Kaczmarczyk M. Sulzyc-Bielicka V. Bielicki D. et al. (2010) Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis. Int J Colorectal Dis 25: 1079-1085.
87. Weber J. (2008) Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 13: 16-25.
88. Yap TA. Yan L. Patnaik A. Fearen I. Olmos D. Papadopoulos K. et al. (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29: 4688-4695.
89. Zhou H. Roy S. Cochran E. Zouaoui R. Chu CL. Duffner J. et al. (2011) M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS 6: e21106.